Navigation Links
Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
Date:12/17/2007

MISSISSAUGA, ON, Dec. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) and Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading European pharmaceutical and medical devices company, today announced the receipt of initial orders for Vasogen's Celacade(TM) System in Germany. Celacade, a first-in-class therapy, is the only CE Mark approved product that specifically targets the destructive chronic inflammation underlying the development and progression of chronic heart failure. Under the CE Mark, Celacade can be marketed in the 27 countries that comprise the European Union and is indicated in the EU for the treatment of New York Heart Association (NYHA) Class II patients and NYHA Class II, III, & IV heart failure patients who do not have a prior history of heart attack.

In the international ACCLAIM trial, Celacade was shown to significantly reduce the risk of death or cardiovascular hospitalizations in large pre-specified subgroups of patients with chronic heart failure, including NYHA Class II patients, where risk was reduced by 39%, and NYHA Class II to IV patients with no prior heart attack, where risk was reduced by 26%. The commercial introduction of Celacade in the European Union provides physicians and patients with a novel approach for the treatment of heart failure that is safe and well tolerated and can be used in combination with currently approved therapies for this condition.

"The initial orders for the Celacade System are a major milestone for Vasogen," commented Chris Waddick, President and CEO of Vasogen. "We are extremely pleased that Ferrer has secured these orders so quickly after completing key pre-marketing activities. We look forward to continuing our close collaboration with Ferrer as we wo
'/>"/>

SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... -- Culot brings life science and software ... BioData, producer of Labguru, the web-based research ... appointment of Louis Culot as the company,s ... and Business Development at BioDiscovery Inc., developer of genomics ... Previously, Culot worked for 17 years with CambridgeSoft ...
(Date:9/1/2014)... 01, 2014 The Collaborative R&D ... report provides comprehensive understanding and unprecedented access to ... by the worlds leading life science companies. , ... of how and why companies enter collaborative R&D ... partner’s negotiated deals terms provides critical insight into ...
(Date:8/31/2014)... This is a professional and in-depth ... Hardener industry in Global and China. The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3
... Leading ... procedures through the roll-out of a global Summer seminar and exhibition programme that ... test methods within the pharmaceutical industry. , ... Belfast (Vocus) May 5, 2010 -- Package integrity is key ...
... Inc. (Pink Sheets: DYAI) ("Dyadic"), a leading-edge early-stage biotechnology company, is pleased to ... , , ... , , ... as Executive Director of Strategic Alliances . Ms. Whitehead brings to Dyadic ...
... MELBOURNE , May 4, 2010 Ansell today announced the ... of the Royal Australasian College of Surgeons in, Perth, Australia . , ... It is the first ... protection to,surgical staff against viruses and bacteria, in the event of a breach ...
Cached Biology Technology:Pharmaceutical Leak Testing Practices challenged by SEPHA 2Pharmaceutical Leak Testing Practices challenged by SEPHA 3Dyadic International Strengthens Management Team 2Dyadic International Strengthens Management Team 3Dyadic International Strengthens Management Team 4Dyadic International Strengthens Management Team 5Ansell Launches Worlds's First Antimicrobial Surgical Glove 2
(Date:8/31/2014)... they are not busy attacking us, germs go after ... always spell disaster for the infected microbes: Sometimes viruses ... to, say, expand its diet or better attack its ... of an immune system would robotically destroy anything it ... Rockefeller University have now revealed that one variety of ...
(Date:8/31/2014)... the past several decades, malaria diagnosis has changed very little. ... smears the blood across a glass slide, stains it with ... Plasmodium parasite, which causes the disease. This approach gives an ... an important measure of disease severity but is ... A research team from the Singapore-MIT Alliance for Research and ...
(Date:8/29/2014)... (Aug. 29, 2014) Scientists at the Barshop Institute ... of Medicine at the UT Health Science Center at ... the tissues of the longest-lived rodent, the naked mole ... the cells of naked mole rats protects and alters ... damaged and obsolete proteins. , The factor also protects ...
Breaking Biology News(10 mins):Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3A new way to diagnose malaria 2A new way to diagnose malaria 3Factor in naked mole rat's cells enhances protein integrity 2
... A new neuroimaging study conducted by researchers from the ... de Montral at the International laboratory for Brain Music ... amusic individuals have more grey matter in specific regions ... the right interior frontal gyrus and the right auditory ...
... Approximately one in every 500 to 650 baby boys is ... genetic code that until a few years ago was thought ... no longer the case. A recent conference hosted by NewYork-Presbyterian ... raising awareness of the condition and the recent availability of ...
... chew up rattlesnake skin and smear it on their ... a new study by researchers at UC Davis. ... UC Davis, observed ground squirrels (Spermophilus beecheyi) and rock ... picking up pieces of shed snakeskin, chewing it and ...
Cached Biology News:Jingle bells not merry for tone-deaf individuals 2Jingle bells not merry for tone-deaf individuals 3Physician-scientists seek solutions to reproductive problems related to chromosomal variations 2Physician-scientists seek solutions to reproductive problems related to chromosomal variations 3
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse anti human pro-Relaxin-2...
Mouse Anti-Human Kallikrein 2 (Hk2)...
Biology Products: